Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

COVID-19

Displaying 1 to 10 of 16 Posts . Displaying 10 of Posts . Page of 2 . Go To Page: . Per Page: . . . View All Sort By: .

Stories from the Field: COVID-19 and Psoriatic Arthritis

US-based rheumatologist and IPC Councilor Arthur Kavanaugh, MD, discusses his plans to continue offering telemedicine appointments to patients after the pandemic. "Telemedicine is a new skill set that [we] providers need to learn," says Dr. Kavanaugh in this week's Stories from the Field video.

Read More

Stories from the Field: Impact of COVID-19 restrictions on psoriasis patients in Egypt

Due to COVID-19 restrictions, patients in Egypt with severe psoriasis are not getting timely access to biologic treatment. IPC Board Member Mahira Hamdy El Sayed, MSc, MD, discusses the potential fallout for Egyptians with psoriasis, post-COVID-19.

Read More

Commentary: Classification of the cutaneous manifestations of COVID-19 via a rapid consensus study in Spain

Dr. Lluís Puig provides his comments on a recent publication on the classification of the cutaneous manifestations of COVID‐19.

Read More

WATCH NOW: PsoProtect International Registry for Psoriasis and COVID-19

Catherine Smith, MD, and Savteer Mahil, MD, talk to IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD, about their goals for the PsoProtect patient registry to study COVID-19 and psoriasis.

Read More

Commentary: COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

Soon after COVID-19 was declared a pandemic, the question if particular patient groups – those with immune-mediated inflammatory disease (IMID) and/or those on an immunosuppressant treatment – are at higher risk to become infected and/or are at risk for developing a more severe course of the disease.

Read More

Commentary: COVID-19 in Immune-Mediated Inflammatory Diseases – Case Series from New York

Commentary from IPC Councilor Mark Lebwohl, MD, on a case series in NEJM on COVID-19 in immune-mediated inflammatory diseases.

Read More

Stories from the Field: Apoyando a nuestros pacientes durante la pandemia de COVID-19 | Claudia De La Cruz, MD

Conexión, conversación, claridad: el miembro de la junta de IPC, Claudia de la Cruz, MD, ofrece consejos sobre cómo comunicarse con pacientes con psoriasis que están preocupados por COVID-19 y su salud.

Read More

Stories from the field: Supporting our patients during the COVID-19 pandemic | Claudia de la Cruz, MD

Connection, conversation, clarity: IPC Director Claudia de la Cruz, MD, offers advice on communicating with psoriasis patients who are worried about COVID-19 and their health.    

Read More

PsoProtect global registry adds option for patients to self-report

ntroducing PsoProtectMe, a registry for people with psoriasis to report on their health now.

Read More

Declaração sobre o surto de Coronavírus (COVID-19)

Para pacientes com psoríase diagnosticados com doença causada pelo COVID-19, o IPC recomenda que médicos interrompam ou adiem o uso de medicamentos imunossupressores. Esta recomendação está em acordo com guias de tratamento já existentes (por exemplo, o European Dermatology Forum e a American Academy of Dermatology), que declaram que tratamentos imunossupressores são contraindicados em pacientes com infecções ativas.

Read More
now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK